Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CyDex Pharmaceuticals and Prism Pharmaceuticals have mutually decided to terminate their existing joint development agreement on novel Captisol-enabled intravenous formulations of Clopidogrel.
Subscribe to our email newsletter
Clopidogrel is the active ingredient in Plavix, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb and Sanofi-Aventis.
The joint decision provides CyDex with full development and commercialisation rights to the product candidate – an injectable formulation of Clopidogrel.
CyDex president and CEO Theron Odlaug said that obtaining full development and commercialisation rights to an onset injectable form of Clopidogrel is an important strategic advance for CyDex as they continue to expand portfolio of products for acute care hospital applications.
"We look forward to establishing a relationship with a strategic outlicensing partner to continue the development of this promising product candidate in the clinic and, after regulatory approval, into the commercial market," Odlaug said.
"We also look forward to building upon our strong relationship with Prism Pharmaceuticals, as they market their Captisol-enabled product Nexterone for treatment of arrhythmia."